Fig. 2: PFS2 based on cytogenetic risk status. | Blood Cancer Journal

Fig. 2: PFS2 based on cytogenetic risk status.

From: Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Fig. 2

PFS2 in the ITT/biomarker risk population:* A standard and B high cytogenetic risk patients. PFS2 in patients with one prior line of therapy: C standard and D high cytogenetic risk patients. PFS2 progression-free survival on the next subsequent line of therapy, D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, HR hazard ratio, CI confidence interval, ITT intent-to-treat. *Patients in the ITT population who met the biomarker criteria for risk assessment.

Back to article page